Equities

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)30.00
  • Today's Change2.25 / 8.11%
  • Shares traded1.35m
  • 1 Year change-37.01%
  • Beta0.8778
Data delayed at least 15 minutes, as of Nov 22 2024 18:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy8
Outperform7
Hold7
Sell0
Strong Sell0

Share price forecast in USD

The 20 analysts offering 12 month price targets for Apellis Pharmaceuticals Inc have a median target of 46.00, with a high estimate of 78.00 and a low estimate of 20.00. The median estimate represents a 65.77% increase from the last price of 27.75.
High181.1%78.00
Med65.8%46.00
Low-27.9%20.00

Earnings history & estimates in USD

On Nov 05, 2024, Apellis Pharmaceuticals Inc reported 3rd quarter 2024 losses of -0.46 per share.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate+13.69%
Apellis Pharmaceuticals Inc reported annual 2023 losses of -4.45 per share on Feb 27, 2024.
Average growth rate-7.05%
More ▼

Revenue history & estimates in USD

Apellis Pharmaceuticals, Inc. had 3rd quarter 2024 revenues of 196.83m. This missed the 200.35m consensus estimate of the 20 analysts following the company. This was 338.90% above the prior year's 3rd quarter results.
Average growth rate+16.19%
Apellis Pharmaceuticals, Inc. had revenues for the full year 2023 of 396.59m. This was 425.83% above the prior year's results.
Average growth rate+121.90%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.